Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

BACKGROUND: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. METHODS: The Tolvaptan Efficacy and Safety Management of ADPKD and its Outcomes (TEMPO) 3:4 study involved baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Marie E, Blais, Jaime D, Czerwiec, Frank S, Erickson, Bradley J, Torres, Vicente E, Kline, Timothy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Familial Nephropathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366146/
https://www.ncbi.nlm.nih.gov/pubmed/30746130
http://dx.doi.org/10.1093/ckj/sfy078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366146/
https://www.ncbi.nlm.nih.gov/pubmed/30746130
http://dx.doi.org/10.1093/ckj/sfy078

Ejemplares similares